Presented at the 55th Annual Meeting of the American Society for Radiation Oncology; Atlanta, Georgia; September 22-25, 2013.
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer
Version of Record online: 30 DEC 2013
© 2013 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 120, Issue 7, pages 1076–1082, 1 April 2014
How to Cite
Hoppe, B. S., Michalski, J. M., Mendenhall, N. P., Morris, C. G., Henderson, R. H., Nichols, R. C., Mendenhall, W. M., Williams, C. R., Regan, M. M., Chipman, J. J., Crociani, C. M., Sandler, H. M., Sanda, M. G. and Hamstra, D. A. (2014), Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer, 120: 1076–1082. doi: 10.1002/cncr.28536
The Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment (PROSTQA) Consortium includes contributions in cohort design, patient accrual, and follow-up from the following investigators: Larry Hembroff (Michigan State University, East Lansing, Mich); John T. Wei and Laurel Northouse (University of Michigan, Ann Arbor, Mich); Eric A. Klein and Jay Ciezki (Cleveland Clinic, Cleveland, Ohio); Gerald Andriole (Washington University, St. Louis, Mo); Mark Litwin and Chris Saigal (University of California-Los Angeles Medical Center, Los Angeles, Calif); Thomas Greenfield, PhD (Berkeley, Calif); Louis Pisters and Deborah Kuban (The University of Texas MD Anderson Cancer Center, Houston, Tex); Jim Hu and Adam Kibel (Brigham and Women's Hospital, Boston, Mass); Douglas Dahl and Anthony Zietman (Massachusetts General Hospital, Boston, Mass); and Peter Chang and Irving Kaplan (Beth Israel Deaconess Medical Center, Boston, Mass).
We acknowledge PROSTQA Data Coordinating Center Project Management by Jill Hardy, MS (Michigan State University, East Lansing, Mich) and Erin Najuch (Dana Farber Cancer Institute, Boston, Mass); grant administration by Beth Doiron, BA (Beth Israel Deaconess Medical Center, Boston, Mass); and technical support from coordinators at each clinical site.
- Issue online: 18 MAR 2014
- Version of Record online: 30 DEC 2013
- Manuscript Accepted: 25 NOV 2013
- Manuscript Revised: 21 NOV 2013
- Manuscript Received: 8 OCT 2013
- 2Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol. 2010;28:1106-1111., , , et al.
- 12Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. Urology. 2010;75:1004-1008., , , et al.